Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

49.43USD
13 Sep 2019
Change (% chg)

$-0.18 (-0.36%)
Prev Close
$49.61
Open
$49.95
Day's High
$50.34
Day's Low
$49.28
Volume
1,663,741
Avg. Vol
2,636,629
52-wk High
$63.69
52-wk Low
$42.49

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Says On September 11, Size Of Board Was Increased To Fourteen
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB CO - ON SEPTEMBER 11, SIZE OF BOARD OF DIRECTORS WAS INCREASED TO FOURTEEN.  Full Article

Bristol‑Myers Squibb Announces Dividend
Wednesday, 11 Sep 2019 

Sept 11 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL‑MYERS SQUIBB ANNOUNCES DIVIDEND.BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY ONE CENTS ($0.41) PER SHARE.  Full Article

Presage Announces Collaboration With Bristol-Myers Squibb For Phase O Studies Of Novel Cancer Agents Utilizing Civo Technology
Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - Presage Biosciences ::PRESAGE ANNOUNCES COLLABORATION WITH BRISTOL-MYERS SQUIBB FOR PHASE O STUDIES OF NOVEL CANCER AGENTS UTILIZING CIVO™ TECHNOLOGY.PRESAGE BIOSCIENCES - ENTERED INTO A RESEARCH COLLABORATION WITH BRISTOL-MYERS SQUIBB COMPANY.BRISTOL-MYERS SQUIBB CO - SPECIFIC TERMS AND DETAILS REGARDING COLLABORATION ARE UNDISCLOSED.PRESAGE BIOSCIENCES SAYS TO EVALUATE EARLY STAGE ONCOLOGY TARGETS IN PHASE 0 TRIALS.PRESAGE BIOSCIENCES SAYS SPECIFIC TERMS AND DETAILS REGARDING COLLABORATION ARE UNDISCLOSED.  Full Article

Catalent Q4 Earnings Per Share $0.44
Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - Catalent Inc ::CATALENT, INC. REPORTS FOURTH QUARTER FISCAL 2019 RESULTS.Q4 EARNINGS PER SHARE $0.44.SEES FY 2020 REVENUE $2.78 BILLION TO $2.88 BILLION.Q4 REVENUE $725.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $721 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.64 -- REFINITIV IBES DATA.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.70.FOR FISCAL 2020 EXPECTS ADJUSTED EBITDA IN RANGE OF $700 MILLION TO $730 MILLION AND ADJUSTED NET INCOME IN RANGE OF $300 MILLION TO $330 MILLION.CATALENT - ANNOUNCED AGREEMENT TO BUY BRISTOL-MYERS SQUIBB'S ORAL SOLID, BIOLOGICS, & STERILE PRODUCT MANUFACTURING & PACKAGING FACILITY IN ANAGNI, ITALY.FY2020 REVENUE VIEW $2.84 BILLION -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, CO HAD $3.0 BILLION IN TOTAL DEBT, AND $2.6 BILLION IN TOTAL DEBT NET OF CASH AND SHORT-TERM INVESTMENTS.  Full Article

Amgen sees SG&A, R&D expenses up in 2020 after Otezla deal
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Amgen ::EXEC SEES 2020 NON-GAAP SG&A EXPENSES UP $600-700 MILLION DUE TO ONGOING COST OF OTEZLA-CONF. CALL.EXEC SEES 2020 NON-GAAP RESEARCH AND DEVELOPMENT OPERATING EXPENSES UP $500 MILLION -CONF. CALL.EXEC SEES 2020 SHARE REPURCHASES CONSISTENT WITH 2015-2018 REPURCHASES, EXCLUDING 2018 TENDER-CONF. CALL.  Full Article

Amgen To Acquire Otezla For $13.4 Bln
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Amgen Inc ::AMGEN TO ACQUIRE OTEZLA® FOR $13.4 BILLION IN CASH, OR APPROXIMATELY $11.2 BILLION NET OF ANTICIPATED FUTURE CASH TAX BENEFITS.AMGEN INC - AMGEN WILL FINANCE TRANSACTION WITH CURRENT BALANCE SHEET CASH AND EXPECTS TO RETAIN ITS INVESTMENT GRADE CREDIT RATING.AMGEN INC - BELIEVES ACQUISITION OF OTEZLA TO BE IMMEDIATELY NON-GAAP EPS ACCRETIVE.AMGEN INC - AMGEN'S CAPITAL ALLOCATION PRIORITIES WILL REMAIN UNCHANGED.AMGEN INC - DEAL FOR ABOUT $11.2 BILLION, NET OF PRESENT VALUE OF $2.2 BILLION IN ANTICIPATED FUTURE CASH TAX BENEFITS.AMGEN INC - EXPECTS AT LEAST LOW DOUBLE-DIGIT OTEZLA SALES GROWTH, ON AVERAGE, OVER NEXT FIVE YEARS.  Full Article

Bristol-Myers Squibb Announces Agreement Between Celgene And Amgen To Divest Otezla For $13.4 Billion
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Bristol-Myers Squibb Co ::PRESS RELEASE - BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA FOR $13.4 BILLION.BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA® FOR $13.4 BILLION.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA® FOR $13.4 BILLION.BRISTOL-MYERS SQUIBB CO - AGREEMENT CONTINGENT ON FTC CONSENT DECREE AND CLOSING OF PENDING BRISTOL-MYERS SQUIBB-CELGENE MERGER.BRISTOL-MYERS SQUIBB CO - AGREEMENT CONTINGENT ON FTC CONSENT DECREE AND CLOSING OF PENDING BRISTOL-MYERS SQUIBB-CELGENE MERGER.BRISTOL-MYERS SQUIBB CO - PENDING BRISTOL-MYERS SQUIBB-CELGENE MERGER EXPECTED TO CLOSE BY END OF 2019.BRISTOL-MYERS SQUIBB CO - AGREEMENT INCLUDES TRANSFER OF CELGENE EMPLOYEES PRIMARILY DEDICATED TO OTEZLA.BRISTOL-MYERS SQUIBB CO - INCREASING ITS PREVIOUSLY PLANNED $5 BILLION ACCELERATED SHARE REPURCHASE TO $7 BILLION.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB PLANS TO PRIORITIZE USE OF PROCEEDS FROM OTEZLA DIVESTITURE FOR DEBT REDUCTION.BRISTOL-MYERS SQUIBB CO - NOW EXPECTS PENDING MERGER WITH CELGENE TO CLOSE BY END OF 2019..BRISTOL-MYERS SQUIBB CO - AMGEN WOULD ACQUIRE GLOBAL RIGHTS TO OTEZLA (APREMILAST) FOR $13.4 BILLION IN CASH.BRISTOL-MYERS SQUIBB CO - PLANS TO PRIORITIZE USE OF PROCEEDS FROM OTEZLA DIVESTITURE FOR DEBT REDUCTION.  Full Article

Ptc Therapeutics Expands In New Jersey With Biologics Facility
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Bristol-Myers Squibb Co ::PTC THERAPEUTICS EXPANDS PRESENCE IN NEW JERSEY BY SECURING STATE-OF-THE-ART BIOLOGICS FACILITY.PTC THERAPEUTICS INC - PTC TO GAIN ACCESS TO HIGHLY-QUALIFIED SPECIALISTS IN BIOLOGICS OPERATIONS.PTC THERAPEUTICS INC - FACILITY WILL SUPPORT GENE THERAPY PRODUCTION.PTC THERAPEUTICS INC - PTC PLANS TO MOVE ITS RESEARCH OPERATIONS TO A NEWLY RENOVATED BUILDING ON SAME CAMPUS.  Full Article

Taisho Pharmaceutical Completes Procedures For Acquisition Of UPSA SAS
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Japan's Taisho Pharmaceutical <4581.T>::COMPLETES PROCEDURES FOR ACQUISITION OF UPSA SAS.  Full Article

Bristol-Myers Squibb Is Planning Divestiture Of Otezla(Apremilast)
Monday, 24 Jun 2019 

June 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB PROVIDES UPDATE ON PENDING MERGER WITH CELGENE.BRISTOL-MYERS SQUIBB CO - COMPANY IS PLANNING DIVESTITURE OF OTEZLA® (APREMILAST)..BRISTOL-MYERS SQUIBB CO - DIVESTITURE IS SUBJECT TO FURTHER REVIEW BY FTC AND REQUIRES THAT BRISTOL-MYERS SQUIBB ENTER INTO A CONSENT DECREE WITH FTC.BRISTOL-MYERS - REMAINS ACTIVELY ENGAGED IN DISCUSSIONS WITH U.S. FTC ON FTC'S CONTINUED REVIEW OF PROPOSED CELGENE TRANSACTION.BRISTOL-MYERS SQUIBB CO - CELGENE TRANSACTION CLOSING DATE CURRENTLY EXPECTED TO BE AT END OF 2019 OR BEGINNING OF 2020..BRISTOL-MYERS SQUIBB CO - PROCEEDS OF OTEZLA SALE WILL ALLOW BRISTOL-MYERS SQUIBB TO ACCELERATE ITS POST-CLOSING DELEVERAGING PLANS.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB AND CELGENE HAVE CONCLUDED THEIR PRE-NOTIFICATION PROCESS WITH EUROPEAN COMMISSION.BRISTOL-MYERS SQUIBB CO - FOR CELGENE DEAL, SUBMITTED FORMAL APPLICATION FOR CLEARANCE BY EUROPEAN COMMISSION.  Full Article

UPDATE 2-Tocagen's brain cancer treatment fails late-stage study, shares crash

Sept 12 Tocagen Inc's shares fell nearly 80% after its experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition.